ResMed Bull Sees Operational Upgrade in Reiterated Guidance — Market Talk

What happened

Macquarie reiterated its outperform rating on ResMed’s Australia-listed shares and raised its target price 1.5% to A$47.50. The analyst said the company’s unchanged annual revenue guidance of US$5.75 billion to US$5.85 billion, despite greater currency headwinds, suggests a slight operational upgrade.

Confirmed

Global impact / market context

The guidance range indicates ResMed expects revenue to hold up despite currency moves that could reduce the value of overseas sales when converted. If the analyst’s operational-upgrade reading is right, stronger underlying performance may be offsetting that pressure, while customer inflation remains a possible risk to demand.

Analyst inference

The article reports ResMed shares down 7.2% at A$32.96, while Macquarie raised its target price and retained an outperform rating. This contrast reflects the analyst’s positive reading of guidance alongside currency and customer-inflation concerns, not evidence that the share decline has reversed.

Confirmed

What to watch

1. Watch ResMed’s reported revenue against its US$5.75 billion to US$5.85 billion annual guidance range; falling short could indicate currency or business pressures are outweighing resilience. Analyst inference
2. Track currency moves and their effect on sales translated into US dollars, since the guidance already assumes increased headwinds from recent exchange-rate changes. Analyst inference
3. Watch for signs that inflation is affecting customers, a risk the Macquarie analyst says remains under review and could influence demand for ResMed’s products. Confirmed

Evidence

• Original source link unavailable